MX2019006598A - Celulas asesinas naturales modificadas geneticamente y sus usos. - Google Patents

Celulas asesinas naturales modificadas geneticamente y sus usos.

Info

Publication number
MX2019006598A
MX2019006598A MX2019006598A MX2019006598A MX2019006598A MX 2019006598 A MX2019006598 A MX 2019006598A MX 2019006598 A MX2019006598 A MX 2019006598A MX 2019006598 A MX2019006598 A MX 2019006598A MX 2019006598 A MX2019006598 A MX 2019006598A
Authority
MX
Mexico
Prior art keywords
natural killer
killer cells
engineered natural
cells
engineered
Prior art date
Application number
MX2019006598A
Other languages
English (en)
Inventor
Eamon Peter O''dwyer Michael
Original Assignee
Onkimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60937693&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019006598(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onkimmune Ltd filed Critical Onkimmune Ltd
Publication of MX2019006598A publication Critical patent/MX2019006598A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001126—CD38 not IgG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4636—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464426—CD38 not IgG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

En la presente descripción se proporcionan células asesinas naturales modificadas genéticamente que se modificaron para expresar los receptores de antígenos quiméricos (CAR). Las células contienen opcionalmente otras modificaciones que mejoran la citotoxicidad específica del tumor y la migración dirigida a los sitios del tumor. Además se contemplan métodos para usar las células asesinas naturales modificadas genéticamente para tratar pacientes con cáncer.
MX2019006598A 2016-12-09 2017-12-11 Celulas asesinas naturales modificadas geneticamente y sus usos. MX2019006598A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662432302P 2016-12-09 2016-12-09
PCT/EP2017/082292 WO2018104562A1 (en) 2016-12-09 2017-12-11 Engineered natural killer cells and uses thereof

Publications (1)

Publication Number Publication Date
MX2019006598A true MX2019006598A (es) 2019-10-15

Family

ID=60937693

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006598A MX2019006598A (es) 2016-12-09 2017-12-11 Celulas asesinas naturales modificadas geneticamente y sus usos.

Country Status (12)

Country Link
US (2) US10799536B2 (es)
EP (4) EP3895712B1 (es)
JP (2) JP7228900B2 (es)
KR (1) KR20190114966A (es)
CN (2) CN117305250A (es)
AU (1) AU2017371517B2 (es)
BR (1) BR112019011450A2 (es)
CA (1) CA3045386A1 (es)
DK (2) DK3454871T3 (es)
ES (3) ES2875005T3 (es)
MX (1) MX2019006598A (es)
WO (1) WO2018104562A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10906951B2 (en) * 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
EP3443001A4 (en) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
WO2018104562A1 (en) 2016-12-09 2018-06-14 Onkimmune Limited Engineered natural killer cells and uses thereof
SG11202011313UA (en) * 2018-05-16 2020-12-30 Res Inst Nationwide Childrens Hospital Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins
KR102653878B1 (ko) * 2018-08-01 2024-04-01 난트퀘스트, 인크. 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템 (a quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies)
EP3843750A4 (en) * 2018-08-29 2022-05-25 Academia Sinica COMBINATION OF NATURAL KILLER CELLS WITH CYCLOPHOSPHAMIDE COMPOUNDS FOR THE TREATMENT OF CANCER
WO2020189942A1 (ko) * 2019-03-15 2020-09-24 한국과학기술연구원 암 상살 능력이 향상된 면역세포
KR102292657B1 (ko) * 2019-03-15 2021-08-24 한국과학기술연구원 암 상살 능력이 향상된 면역세포
CN109970869A (zh) * 2019-04-12 2019-07-05 南京卡提医学科技有限公司 一种靶向人trail死亡受体的嵌合受体配体及其应用
WO2020220027A1 (en) * 2019-04-25 2020-10-29 Purdue Research Foundation Engineered natural killer cells redirected toward purinergic signaling, constructs thereof, and methods for using the same
CA3156509A1 (en) * 2019-10-31 2021-05-06 Research Institute At Nationwide Children's Hospital Generation of cd38 knock-out primary and expanded human nk cells
WO2021146521A1 (en) * 2020-01-16 2021-07-22 Acepodia Biotechnologies Ltd. A novel cd16+ natural killer cell and a method of culturing cd16+ natural killer cell
WO2021209625A1 (en) * 2020-04-17 2021-10-21 Onk Therapeutics Limited High potency natural killer cells
WO2022047419A1 (en) 2020-08-31 2022-03-03 City Of Hope Novel cell lines, methods of producing natural killer cells and uses thereof
CN114426583B (zh) * 2020-10-29 2023-10-10 中国科学技术大学 用于急性髓系白血病的细胞疗法的嵌合抗原受体
WO2022139517A1 (ko) * 2020-12-23 2022-06-30 주식회사 휴먼셀바이오 혈액 유래 물질 및 면역세포를 포함하는 암 또는 면역질환의 예방 또는 치료용 약학조성물
EP4355860A1 (en) 2021-06-18 2024-04-24 ONK Therapeutics Limited Double knockout natural killer cells
CA3225985A1 (en) 2021-07-01 2023-01-05 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
CA3231204A1 (en) * 2021-09-18 2023-03-23 Feng Wang-Johanning Herv-k antibody, cell, vaccine, and drug therapeutics
WO2023102201A2 (en) * 2021-12-03 2023-06-08 University Of Utah Research Foundation High selective cd229 antigen binding domains and methods of use
WO2024007020A1 (en) 2022-06-30 2024-01-04 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods
EP4353741A1 (en) 2022-10-14 2024-04-17 ONK Therapeutics Limited Double knockout natural killer cells

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004213432A1 (en) * 2003-02-14 2004-09-02 Sagres Discovery, Inc. Novel therapeutic targets in cancer
SG10201912554TA (en) 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
SI2081595T1 (sl) 2006-09-26 2019-10-30 Genmab As Anti-cd38 plus kortikosteroidi plus ne-kortikosteroidni kemoterapevtik za zdravljenje tumorjev
JP2010507366A (ja) 2006-10-19 2010-03-11 メルク アンド カンパニー インコーポレイテッド インターロイキン−１３受容体α１の抗体アンタゴニスト
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
SI2580243T1 (sl) 2010-06-09 2020-02-28 Genmab A/S Protitelesa proti humanemu CD38
ES2671004T3 (es) 2013-03-07 2018-06-04 Baylor College Of Medicine Dirección a CD138 en cáncer
EP3104866A4 (en) * 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
US10836998B2 (en) * 2014-02-14 2020-11-17 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
JP6768664B2 (ja) 2014-12-24 2020-10-14 アーディジェン， エルエルシー 分子の細胞内送達のためのペプチドおよびナノ粒子
KR20170100653A (ko) 2014-12-31 2017-09-04 안트로제네시스 코포레이션 천연 킬러 세포를 사용하여 혈액학적 장애, 고형 종양, 또는 감염 질환을 치료하는 방법
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CA3172801A1 (en) 2015-06-12 2016-12-15 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
CN115058395A (zh) 2015-06-25 2022-09-16 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
CA3156128A1 (en) 2015-07-29 2017-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2018104562A1 (en) * 2016-12-09 2018-06-14 Onkimmune Limited Engineered natural killer cells and uses thereof

Also Published As

Publication number Publication date
DK3581190T3 (da) 2021-06-07
US20180161371A1 (en) 2018-06-14
JP7228900B2 (ja) 2023-02-27
DK3454871T3 (da) 2019-09-16
ES2746856T3 (es) 2020-03-09
AU2017371517A1 (en) 2019-07-04
US10799536B2 (en) 2020-10-13
ES2875005T3 (es) 2021-11-08
RU2019121509A (ru) 2021-01-11
RU2019121509A3 (es) 2021-03-30
EP3895712B1 (en) 2022-06-22
CN117305250A (zh) 2023-12-29
EP3454871B1 (en) 2019-06-26
CN110248669B (zh) 2023-09-08
EP4104841A1 (en) 2022-12-21
BR112019011450A2 (pt) 2019-10-15
EP3895712A1 (en) 2021-10-20
ES2926397T3 (es) 2022-10-26
CN110248669A (zh) 2019-09-17
EP3581190B1 (en) 2021-03-10
KR20190114966A (ko) 2019-10-10
JP2020503891A (ja) 2020-02-06
EP3581190A1 (en) 2019-12-18
EP3454871A1 (en) 2019-03-20
AU2017371517B2 (en) 2023-01-05
JP2023052980A (ja) 2023-04-12
WO2018104562A1 (en) 2018-06-14
CA3045386A1 (en) 2018-06-14
US20210046118A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
MX2019006598A (es) Celulas asesinas naturales modificadas geneticamente y sus usos.
PH12019500193A1 (en) Chimeric antigen receptors targeting bcma and methods of use thereof
PH12020551160A1 (en) Chimeric antigen receptors targeting cd70
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
PH12016501680A1 (en) Anti-egfrviii antibodies and uses thereof
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
EP3964527A3 (en) Combination therapy for cancer
PH12016501411B1 (en) Bifunctional cytotoxic agents
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2017001008A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33.
MY181834A (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor
MX2016016881A (es) Anticuerpos que se unen a axl.
NZ731782A (en) Pyrrolobenzodiazepine-antibody conjugates
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
PH12020550964A1 (en) Heavy chain antibodies binding to cd22
MX2018004121A (es) Receptores de antigeno y usos de los mismos.
MX2019006852A (es) Composiciones y metodos para modular el sistema inmunologico.
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.
PH12017501930A1 (en) Calicheamicin contructs and methods of use
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MX2018013484A (es) Nuevos anticuerpos anti-tnfrsf21 y modos de uso.
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.